

CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL

Authors: Mazyar Shadman,¹ Arnon Kater,² Jennifer Woyach,³ Jianyong Li,⁴ Talha Munir,⁵ Tommi Salmi,⁶ Patrick Phuong,⁶ Tian Tian,⁶ Piers Patten^{7,8}

Affiliations: ¹Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ²Department of Hematology Lymphoma and Myeloma Research Amsterdam, The Netherlands; ³Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; ⁴Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, China; ⁵St James's Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁶BeiGene International GmbH, Basel, Switzerland and BeiGene USA, Inc, San Mateo, CA, USA; ⁷Comprehensive Cancer Centre, King's College London, London, UK; ⁸Department of Haematological Medicine, King's College Hospital, London, UK

Background: The combination of venetoclax (ven), the first-generation BCL2 inhibitor, and ibrutinib, a BTK inhibitor, has demonstrated efficacy in patients with CLL (Wierda et al. *J Clin Oncol.* 2021); however, the toxicity profile of this regimen suggests a need for a more tolerable BTK/BCL2 inhibitor combination. Sonrotoclax, a next generation BCL2 inhibitor, is a more selective and more pharmacologically potent inhibitor of BCL2 than venetoclax. In a phase 1 study in patients with TN CLL treated with sonrotoclax + zanubrutinib, efficacy data was promising with ORR and 1-year progression-free survival (PFS) rates of 100% and deep responses based on undetectable measurable residual disease at $<10^{-4}$ sensitivity (uMRD4). The most common grade ≥ 3 TEAE was neutropenia, and no tumor lysis syndrome or cardiac toxicity was observed (Tam et al. *Blood.* 2023). Zanubrutinib, a next-generation BTK inhibitor, significantly improved PFS and had a more tolerable safety profile, including fewer cardiac adverse events vs ibrutinib in a randomized, head-to-head study of patients with CLL/SLL (Brown et al. *N Engl J Med.* 2023). Presented here is the design of a phase 3 trial aimed at comparing the efficacy of sonrotoclax + zanubrutinib vs ven + obinutuzumab (obi) in patients with TN CLL.

Methods: CELESTIAL-TNCLL (BGB-11417-301; NCT06073821) is a randomized, open-label, phase 3 study. Eligible patients must have previously untreated CLL that requires treatment per 2018 iwCLL criteria, measurable disease by CT/MRI, an ECOG performance score of 0-2, and adequate hematologic and organ function. Approximately 640 patients will be randomized 1:1 to receive either 3 cycles of zanubrutinib monotherapy (320 mg total daily dose, orally), followed by zanubrutinib + sonrotoclax for 12 cycles, or standard ven + obi treatment for 12 cycles. Randomization will be stratified by age (<65 vs ≥65 years) and IGHV and del(17p)/*TP53* mutation status. The primary endpoint is PFS as assessed by independent review committee (IRC) according to 2018 iwCLL guidelines with modifications for treatment-related lymphocytosis for patients with CLL (Cheson et al. 2012). Key secondary endpoints include complete response rate (CRR), defined as CR or CR with incomplete hematopoietic recovery, assessed by IRC; rates of uMRD4 in bone marrow and peripheral blood at the first post-treatment follow-up visit based on next-generation sequencing by clonoSEQ®; and overall survival. Other secondary endpoints include PFS as assessed by investigator (INV); CRR by INV; rate of uMRD4 based on flow cytometry; overall response rate by IRC and INV; duration of response by IRC and INV; patient-reported outcomes; and safety and tolerability. Recruitment is ongoing.